Investor Presentaiton
India Business
India Business: Q3FY22 Sales of 18,156 million (19.9% YoY growth)
.
India sales contributed 70.2% to total sales in Q3FY22
.
.
•
In 9MFY22, the Company's secondary sales grew by 31.7% YoY compared to IPM growth of 21.1% YoY (Source: IQVIA data)
Growth was mainly led by acute therapies like anti-infectives, vitamins / minerals / nutrients, gastrointestinal and pain management
segment helped by COVID-19 tailwinds
During 9MFY22, the Company also outperformed IPM in the chronic therapies like neuro / CNS, cardiac, anti-diabetes and derma
Company's Trade Generic business delivered a robust growth during the quarter and nine months, despite the high base of last
financial year
Q3FY22 - India Sales (* mn)
9MFY22 - India Sales (* mn)
15,140
YOY: 19.9%
18,156
42,264
YoY: 34.5%
56,858
Q3FY21
Q3FY22
9MFY21
9MFY22
O
e
ALKEMView entire presentation